The prevention of foodborne diseases is one of the main objectives of the health authorities. For this purpose, analytical techniques for detecting and / or quantifying the microbiological contamination of food prior to release on the market are required. The management and control of pathogens of food origin have generally been based on conventional detection methodologies, which do not only consume a lot of time and labor, but also involve high consumer material costs. However, this management perspective has changed over time that the food industry requires effective analytical methods that achieve quick results.
This review covers the historical context of traditional methods and their passage in the latest developments of rapid methods and their implementation in the food sector. Improvements and limitations in the detection of the most relevant pathogens are discussed from a perspective applicable to the current situation in the food industry. Given the efforts and recent developments, fast and accurate methods already used in the food industry will also be affordable and portable and provide connectivity in the near future, which improves decision-making and safety throughout the chain Food. A retrospective epidemiological study describing the characteristics, the incidence rates (IR) and the microbiological etiology of the SCAP in Central Australia.
Adult Patients Admitted to Alice Springs Hospital Intensive Care Unit (ICU) between 2011-2014 which has been included the IDSA / ATS definition of the SCAP. Medical records have been examined and compared between Aboriginal and non-Aboriginal patients. Primary results were an incidence rate and microbiological etiology of SCAP. Secondary results were 30 days mortality and a residence time of the ICU and the hospital (LOS).
Plancostomycetes as bacteria associated with the host: a perspective that keeps the promise of their future isolates, imitating their aboriginal environmental niches in clinical microbiology laboratories
Traditionally recognized as environmental bacteria, plancostomycetes have recently been linked to human pathology as opportunistic pathogens, providing great interest to clinical microbiologists. However, the absence of appropriate culture media limits our future surveys because no plackctomyte has ever been isolated from patient specimens despite multiple attempts. Several plancostomycetes have no cultivable members and are recognized only by detecting and analyzing the sequence of the arrn genes. Cultivated representatives are tedious slow growth bacteria and most of the time culture on synthetic media.
As a result, the provision of environmental and nutritional conditions such as those existing in natural habitat in natural habitat where non-skin / refractory bacteria can be detected could be an option for their potential isolation. As a result, we have systematically examined the different natural plancostomycete habitats, to examine their nutritional requirements, the physicochemical characteristics of their natural ecological niches, the current methods of cultivation of plackcetes and gaps, from a perspective of data collection. to optimize the conditions and the culture protocols of these tedious bacteria.
Plancptomycetes are prevalent in freshwater, seawater and terrestrial environments, mainly associated with particles or organisms such as macroalgae, marine sponges and lichens, depending on the species and polysaccharides metabolizable by their sulfatasis. Most plancostomycetes are developing in poor nutrient oligotrophic environments with a pH ranging from 3.4 to 11, but some strains can also develop in media rich in nutrients such as M600 / M14. In addition, a variation in seasonality of abundance is observed and flowering occurs in the summer-early autumn, correlated with strong algae growth in marine environments. Most placalcètes are mesophilic, but with some plancostomycetes being thermophilic (50 ° C to 60 ° C).
From hazard analysis to risk control using rapid methods in microbiology: A practical approach for the food industry
Mini Review: Clinical Routine Microbiology in the Era of Digital Automation and Health
Clinical microbiology laboratories are the first line of infectious disease and antibiotic resistance, including new emerging. Although most clinical laboratories are still based on conventional methods, a cascade of technological change, driven by digital imaging and high-speed sequencing, will revolutionize clinical diagnostics management for direct detection of bacteria and susceptibility testing. rapid antimicrobial. IMPORTANT, such technological advances occur in the golden age of machines learning where computers do not act more passively in the mining of data, but once trained, can also help doctors take Decisions on the optimal diagnosis and administration of treatment.
The additional physical integration potential of new technologies in an automation chain, associated with the software to the automatic learning of data analyzes, is seduced and lead to faster management of infectious diseases. However, if, on the one hand, the technological advancement would have a better performance than conventional methods, on the other side, this evolution disputes clinicians in terms of data interpretation and impact on the whole of the Organization and management of the staff of the hospital.
Description: Enzyme-linked immunosorbent assay kit for quantification of General Histamine in samples from serum, plasma, tissue homogenates and other biological fluids.
Gentaur's HIS ELISA kit utilizes the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with HIS. During the reaction, HIS in the sample or standard competes with a fixed amount of HIS on the solid phase suppo
Description: Quantitative sandwich ELISA for measuring Mouse Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Histamine in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
A monoclonal antibody specific to Histamine (HA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Histamine (HA) and unlabeled Histamine (HA) (Standards or samples) with the pre-coated antibo
Description: A competitive Inhibition ELISA kit for detection of Histamine from General in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
A monoclonal antibody specific to Hyaluronic Acid (HA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Hyaluronic Acid (HA) and unlabeled Hyaluronic Acid (HA) (Standards or samples) with the
Description: A competitive Inhibition ELISA kit for detection of Histamine from General in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
Description: Vanoxerine is an antagonist of dopamine transporter (DAT1) with Ki value of 16.9nM [1].As an antagonist of DAT, vanoxerine is developed for treatment of Parkinson's disease and depression but has no effect on these diseases.
Description: Vanoxerine is an antagonist of dopamine transporter (DAT1) with Ki value of 16.9nM [1].As an antagonist of DAT, vanoxerine is developed for treatment of Parkinson's disease and depression but has no effect on these diseases.
Description: Vanoxerine is an antagonist of dopamine transporter (DAT1) with Ki value of 16.9nM [1].As an antagonist of DAT, vanoxerine is developed for treatment of Parkinson's disease and depression but has no effect on these diseases.
Description: IT1t dihydrochloride is a potent antagonist of CXCR4 with IC50 value of 8.0 nM [1]. C-X-C chemokine receptor type 4 (CXCR4) is an ?-chemokine receptor for chemokine CXCL12.
Description: IT1t dihydrochloride is a potent antagonist of CXCR4 with IC50 value of 8.0 nM [1]. C-X-C chemokine receptor type 4 (CXCR4) is an ?-chemokine receptor for chemokine CXCL12.
Description: IT1t dihydrochloride is a potent antagonist of CXCR4 with IC50 value of 8.0 nM [1]. C-X-C chemokine receptor type 4 (CXCR4) is an ?-chemokine receptor for chemokine CXCL12.
Description: IT1t dihydrochloride is a potent antagonist of CXCR4 with IC50 value of 8.0 nM [1]. C-X-C chemokine receptor type 4 (CXCR4) is an ?-chemokine receptor for chemokine CXCL12.
Description: IT1t dihydrochloride is a potent antagonist of CXCR4 with IC50 value of 8.0 nM [1]. C-X-C chemokine receptor type 4 (CXCR4) is an ?-chemokine receptor for chemokine CXCL12.
Description: IT1t dihydrochloride is a potent antagonist of CXCR4 with IC50 value of 8.0 nM [1]. C-X-C chemokine receptor type 4 (CXCR4) is an ?-chemokine receptor for chemokine CXCL12.
Description: EC50: 1.24 ?MFluphenazine is a dopamine D1 and D2 receptor inhibitor.Dopamine D1 and D2 receptor immunohistochemistry has been used to study the structure of the adult rat arcuate-median eminence complex, particularly in relation to the tubero-infundibular dopamine neurons.
Description: EC50: 1.24 ?MFluphenazine is a dopamine D1 and D2 receptor inhibitor.Dopamine D1 and D2 receptor immunohistochemistry has been used to study the structure of the adult rat arcuate-median eminence complex, particularly in relation to the tubero-infundibular dopamine neurons.
Description: 1400W dihydrochloride is a potent and selective inhibitor of inducible nitric oxide synthase with Kd value of 7 nM [1]. Inducible nitric oxide synthase (iNOS) is an enzyme catalyzing the production of nitric oxide (NO) and is involved in immune response.
Description: 1400W dihydrochloride is a potent and selective inhibitor of inducible nitric oxide synthase with Kd value of 7 nM [1]. Inducible nitric oxide synthase (iNOS) is an enzyme catalyzing the production of nitric oxide (NO) and is involved in immune response.
Description: 1400W dihydrochloride is a potent and selective inhibitor of inducible nitric oxide synthase with Kd value of 7 nM [1]. Inducible nitric oxide synthase (iNOS) is an enzyme catalyzing the production of nitric oxide (NO) and is involved in immune response.
Description: Mizolastine dihydrochloride is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.
Description: Mizolastine dihydrochloride is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.
Description: Mizolastine dihydrochloride is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.
Description: MIC: 10-100 ?g/mL in most of the strainsFlupenthixol, introduced in 1965 by Lundbeck, marketed under brand names such asDepixol.Flupenthixolis atypical antipsychoticdrugof thethioxantheneclass.
In this mini-examination, we discuss such technological achievements offering practical examples of their operability, but also their limits and potential problems that their implementation could increase in clinical microbiology laboratories.
Gina
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)